

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name: [Aulos Bioscience](#)\* Website: <https://aulosbio.com>\*

CEO name: [Aron Knickerbocker](#)\*

CATEGORY: [Biotech/Pharma](#)\*

### SESSIONS:

- [Redefining the fight against Cancer: New Targets and Novel Therapeutic Modalities](#)
- [Executive Summary](#)

[Aulos Bioscience is an immuno-oncology company developing next-generation interleukin-2 \(IL-2\) therapeutics that are computationally engineered to mobilize a patient's immune system against cancer. Its lead program—is the first AI-derived antibody to reach human trials and has already demonstrated durable anti-tumor activity with a favorable safety profile in heavily pre-treated patients.](#)

- [Core Technology](#)

[AU-007 binds precisely to the CD25-binding region of IL-2, blocking IL-2–driven regulatory T-cell expansion and vascular endothelium binding while preserving signaling through effector T-cells and NK-cells. The result is potent anti-tumor immunity without the vascular-leak toxicity historically associated with high-dose IL-2.](#)

- [Product Profile/Pipeline:](#)

[AU-007 is a human IgG1 mAb, now being investigated in a Phase 2 clinical trial \(multiple solid tumors\). Best-in-class potential based on selective IL-2 redirection and early signs of clinical activity.](#)

- [Business Strategy:](#)

[Aulos targets well-validated cytokine pathways where legacy therapeutics are limited by narrow therapeutic windows. By pairing AI-guided antibody engineering with focused clinical development, the company aims to deliver differentiated monotherapy efficacy and create combination-ready assets. Aulos maintains full ownership of AU-007 while selectively exploring strategic partnerships and capital-efficient financing to expand its IL-2 franchise.](#)

### [What's Next?](#)

[Complete ongoing Phase 2 dose-expansion cohorts and define the registrational path for AU-007 in melanoma and other tumor types.](#)